Approval of Danicopan, a Novel Complement Inhibitor, for Paroxysmal Nocturnal Hemoglobinuria in Europe

The European Commission has approved danicopan, a first-in-class complement factor D inhibitor, as an add-on therapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and continuing clinically significant extravascular hemolysis despite treatment with standard complement blockade.